Pictet Asset Management
ADMA icon

Pictet Asset Management’s ADMA Biologics ADMA Stock Holding History

Pictet Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$343K Hold
41,036
– – ﹤0.01% 1711
2026
Q1 		$370K Sell
41,036
-120,798
-75% -$1.91M ﹤0.01% 1626
2025
Q4 		$3.06M Sell
161,834
-44,366
-22% -$748K ﹤0.01% 851
2025
Q3 		$3.03M Buy
206,200
+36,338
+21% +$623K ﹤0.01% 835
2025
Q2 		$3.09M Buy
169,862
+133,950
+373% +$2.73M ﹤0.01% 832
2025
Q1 		$712K Buy
35,912
+5,027
+16% +$86.9K ﹤0.01% 1204
2024
Q4 		$530K Buy
30,885
+2,928
+10% +$55.1K ﹤0.01% 1340
2024
Q3 		$558K Sell
27,957
-3,374
-11% -$52.5K ﹤0.01% 1295
2024
Q2 		$350K Hold
31,331
– – ﹤0.01% 1441
2024
Q1 		$207K Buy
31,331
+3,715
+13% +$20.3K ﹤0.01% 1757
2023
Q4 		$125K Buy
27,616
+12,920
+88% +$47.8K ﹤0.01% 1842
2023
Q3 		$52.6K Buy
+14,696
New +$56.6K ﹤0.01% 1905

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Pictet Asset Management's ADMA Position: Q2 2026 in Review

Pictet Asset Management held its ADMA Biologics (ADMA) position steady in Q2 2026 at 41,036 shares worth $343K. The position accounts for ﹤0.01% of the portfolio, ranked #1711.

Pictet Asset Management first reported a position in ADMA in Q3 2023 and has held it in 12 quarters since. The position peaked at $3.09M in Q2 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Pictet Asset Management held 41,036 shares of ADMA Biologics worth $343K as of Q2 2026.
  • Pictet Asset Management left its ADMA Biologics share count unchanged in Q2 2026.
  • ADMA Biologics made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #1711 holding.
  • Pictet Asset Management first reported a position in ADMA Biologics in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's ADMA Biologics position peaked at $3.09M in Q2 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.